Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use.

IF 2.8 3区医学 Q1 OBSTETRICS & GYNECOLOGY

Menopause: The Journal of The North American Menopause Society Pub Date : 2024-04-01 Epub Date: 2024-03-05 DOI:10.1097/GME.0000000000002310

Maria D Hurtado, Elif Tama, Sima Fansa, Wissam Ghusn, Diego Anazco, Andres Acosta, Stephanie S Faubion, Chrisandra L Shufelt

{"title":"Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use.","authors":"Maria D Hurtado, Elif Tama, Sima Fansa, Wissam Ghusn, Diego Anazco, Andres Acosta, Stephanie S Faubion, Chrisandra L Shufelt","doi":"10.1097/GME.0000000000002310","DOIUrl":null,"url":null,"abstract":"Objective: To compare weight loss response and changes in cardiometabolic risk markers in postmenopausal women using semaglutide with and without menopause hormone therapy (HT) use.Methods: Retrospective cohort study of postmenopausal women treated with semaglutide for overweight or obesity for ≥3 months. Endpoints: total body weight loss percentage (TBWL%) at 3, 6, 9, and 12 months after semaglutide initiation; and percentage of women achieving ≥5% and ≥10% TBWL and changes in cardiometabolic risk markers (glucose, blood pressure, and lipids) at 12 months.Results: There were 16 women on HT and 90 on no-HT; mean age 56 ± 8 vs 59 ± 8 yr, P = 0.2 and mean BMI 36 ± 5 vs 39 ± 8 kg/m 2 , P = 0.1; respectively. Among women on no-HT, White race, dyslipidemia, and depression were more prevalent. Women on HT had a higher TBWL% at 3, 6, 9, and 12 months: 7 ± 3% vs 5 ± 4%, P = 0.01; 13 ± 6% vs 9 ± 5%, P = 0.01; 15 ± 6% vs 10 ± 6%, P = 0.02; and 16 ± 6% vs 12 ± 8%, P = 0.04; respectively. After adjusting for potential confounders, this association remained significant across time. At 12 months, a greater percentage of women on HT achieved ≥5% and ≥10% TBWL. Both groups experienced an improvement in cardiometabolic risk markers.Conclusion: In postmenopausal women with overweight or obesity treated with semaglutide, HT use was associated with an improved weight loss response. This association was maintained when adjusted for confounders. Larger studies should be conducted to confirm these results.","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11209769/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Menopause: The Journal of The North American Menopause Society","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/GME.0000000000002310","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To compare weight loss response and changes in cardiometabolic risk markers in postmenopausal women using semaglutide with and without menopause hormone therapy (HT) use.

Methods: Retrospective cohort study of postmenopausal women treated with semaglutide for overweight or obesity for ≥3 months. Endpoints: total body weight loss percentage (TBWL%) at 3, 6, 9, and 12 months after semaglutide initiation; and percentage of women achieving ≥5% and ≥10% TBWL and changes in cardiometabolic risk markers (glucose, blood pressure, and lipids) at 12 months.

Results: There were 16 women on HT and 90 on no-HT; mean age 56 ± 8 vs 59 ± 8 yr, P = 0.2 and mean BMI 36 ± 5 vs 39 ± 8 kg/m 2 , P = 0.1; respectively. Among women on no-HT, White race, dyslipidemia, and depression were more prevalent. Women on HT had a higher TBWL% at 3, 6, 9, and 12 months: 7 ± 3% vs 5 ± 4%, P = 0.01; 13 ± 6% vs 9 ± 5%, P = 0.01; 15 ± 6% vs 10 ± 6%, P = 0.02; and 16 ± 6% vs 12 ± 8%, P = 0.04; respectively. After adjusting for potential confounders, this association remained significant across time. At 12 months, a greater percentage of women on HT achieved ≥5% and ≥10% TBWL. Both groups experienced an improvement in cardiometabolic risk markers.

Conclusion: In postmenopausal women with overweight or obesity treated with semaglutide, HT use was associated with an improved weight loss response. This association was maintained when adjusted for confounders. Larger studies should be conducted to confirm these results.

查看原文本刊更多论文

使用或未使用激素疗法的绝经后妇女对塞马鲁肽的减肥反应。

目的比较使用和未使用绝经激素疗法（HT）的绝经后妇女的体重减轻反应和心脏代谢风险指标的变化：方法：对使用semaglutide治疗超重或肥胖症≥3个月的绝经后妇女进行回顾性队列研究。终点：开始使用塞马鲁肽后3、6、9和12个月的总体重减轻百分比（TBWL%）；12个月后TBWL达到≥5%和≥10%的妇女百分比以及心脏代谢风险指标（血糖、血压和血脂）的变化：16名女性接受了高密度脂蛋白胆固醇治疗，90名女性未接受高密度脂蛋白胆固醇治疗；平均年龄分别为56±8岁和59±8岁，P=0.2；平均体重指数分别为36±5和39±8 kg/m2，P=0.1。在不使用高血压治疗的女性中，白种人、血脂异常和抑郁症的发病率更高。在 3 个月、6 个月、9 个月和 12 个月时，接受高密度脂蛋白血症治疗的女性的 TBWL% 较高：分别为：7 ± 3% vs 5 ± 4%，P = 0.01；13 ± 6% vs 9 ± 5%，P = 0.01；15 ± 6% vs 10 ± 6%，P = 0.02；16 ± 6% vs 12 ± 8%，P = 0.04。在对潜在的混杂因素进行调整后，这种关联在不同时期仍然显著。在 12 个月时，更多接受高热能疗法的女性达到了≥5% 和≥10% 的 TBWL。两组妇女的心脏代谢风险指标均有所改善：结论：在使用塞马鲁肽治疗超重或肥胖的绝经后妇女中，使用高催乳激素与体重减轻反应的改善有关。在对混杂因素进行调整后，这种关联依然存在。应进行更大规模的研究来证实这些结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Menopause: The Journal of The North American Menopause Society 医学-妇产科学

CiteScore

5.40

自引率

7.40%

发文量

330

审稿时长

3-8 weeks

期刊介绍： Menopause, published monthly, provides a forum for new research, applied basic science, and clinical guidelines on all aspects of menopause. The scope and usefulness of the journal extend beyond gynecology, encompassing many varied biomedical areas, including internal medicine, family practice, medical subspecialties such as cardiology and geriatrics, epidemiology, pathology, sociology, psychology, anthropology, and pharmacology. This forum is essential to help integrate these areas, highlight needs for future research, and enhance health care.